Nanoaggregate-forming lipid-conjugated AS1411 aptamer AS a promising tumor-targeted delivery system of anticancer agents in vitro.

Fiche publication

Date publication

juin 2021

Journal

Nanomedicine : nanotechnology, biology, and medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe

Tous les auteurs :
Carvalho J, Lopes-Nunes J, Vialet B, Rosado T, Gallardo E, Vale J, Eloy C, Ferreira S, Palmeira-de-Oliveira R, Campello MPC, Paulo A, Barthélémy P, Mergny JL, Salgado GF, Queiroz JA, Ellington AD, Cruz C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34174419

Résumé

Nanoparticles offer targeted delivery of drugs with minimal toxicity to surrounding healthy tissue and have great potential in the management of human papillomavirus (HPV)-related diseases. We synthesized lipid-modified AS1411 aptamers capable of forming nanoaggregates in solution containing Mg. The nanoaggregates presented suitable properties for pharmaceutical applications such as small size (100nm), negative charge, and drug release. The nanoaggregates were loaded with acridine orange derivative C for its specific delivery into cervical cancer cell lines and HPV-positive tissue biopsies. This improved inhibition of HeLa proliferation and cell uptake without significantly affecting healthy cells. Finally, the nanoaggregates were incorporated in a gel formulation with promising tissue retention properties aiming at developing a local delivery strategy of the nanoaggregates in the female genital tract. Collectively, these findings suggest that the nanoformulation protocol has great potential for the delivery of both anticancer and antiviral agents, becoming a novel modality for cervical cancer management.